Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

CMS Report Points To Barrier To Broader Use Of Home Hemodialysis

This article was originally published in The Gray Sheet

  • News

Executive Summary

A long-awaited CMS 1report to Congress proposing changes to payments for end-stage renal disease treatments states that payments for training patients to use home hemodialysis equipment are outdated and likely inadequate

You may also be interested in...



Home Dialysis Firm Sees Window To Broader Payment In 2008 Medicare Act

Home dialysis stakeholders see opportunities for improvements in Medicare coverage of home dialysis therapy in legislation enacted in July

Home Dialysis Firm Sees Window To Broader Payment In 2008 Medicare Act

Home dialysis stakeholders see opportunities for improvements in Medicare coverage of home dialysis therapy in legislation enacted in July

Fresenius Acquires Renal Solutions, Next-Gen Home Dialysis Technology

The Nov. 29 acquisition of Renal Solutions Inc. (RSI) by Fresenius Medical Care is expected to give Fresenius a better hold on the home therapy market for kidney dialysis

Table

View full table

Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT025799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By